COMPANY
Cresilon
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Spring Biotechnology Internship 2027 | Brooklyn, New York, United States | Sep 23, 2026 | Oct 11, 2026 |
| Preclinical Principal Scientist, Research & Development | Brooklyn, New York, United States | Sep 1, 2026 | Oct 11, 2026 |
| Director of Research & Development | Brooklyn, New York, United States | Sep 1, 2026 | Oct 11, 2026 |
| Manager/Principal Scientist Research & Development - Polymer Formulation | Brooklyn, New York, United States | Sep 1, 2026 | Oct 11, 2026 |
| Senior Medical Device Research and Development Engineer | Brooklyn, New York, United States | Sep 1, 2026 | Oct 11, 2026 |
Funding and NIH signals
- SEC Form D raise Raised $29M in debt securities (Form D filed Apr 29, 2026; amended Jun 26, 2026); +1 other Form D filing in the last 12 months; 7 roles open. SEC Form D 0001728054-26-000001 (Apr 29, 2026)
Evidence (2 events)
- Apr 29, 2026 · SEC Form D 0001728054-26-000001
Name of Issuer: Cresilon, Inc.; CIK: 1728054; Address: Brooklyn, NY; Submission type: D; Filing date: 2026-04-29; Industry Group: Biotechnology; Date of First Sale: 2026-04-24; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 25000000; Total Amount Sold: 4997000; Federal exemptions: 06b || Name of Issuer: Cresilon, Inc.; CIK: 1728054; Address: Brooklyn, NY; Submission type: D/A; Filing date: 2026-06-26; Industry Group: Biotechnology; Date of First Sale: 2026-04-24; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 29000000; Total Amount Sold: 28999199; Federal exemptions: 06c - Dec 8, 2025 · SEC Form D 0001728054-25-000004
Name of Issuer: Cresilon, Inc.; CIK: 1728054; Address: Brooklyn, NY; Submission type: D; Filing date: 2025-12-08; Industry Group: Biotechnology; Date of First Sale: 2025-11-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6716808; Total Amount Sold: 6683401; Federal exemptions: 06c
- Apr 29, 2026 · SEC Form D 0001728054-26-000001
Timeline
- FDA FDA 510(k) clearance: TRAUMAGEL® 2.0 Hemostatic Gel — K253609, Dec 12, 2025. Applicant at approval: Cresilon, Inc. source ↗
FDA records (last 2 years)
- FDA 510(k) clearance: TRAUMAGEL® 2.0 Hemostatic Gel — K253609, Dec 12, 2025. Applicant at approval: Cresilon, Inc. source ↗
Open jobs 7
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Spring Biotechnology Internship 2027 | Brooklyn, New York, United States | Sep 23, 2026 | Oct 11, 2026 | Entry |
| Preclinical Principal Scientist, Research & Development | Brooklyn, New York, United States | Sep 1, 2026 | Oct 11, 2026 | Senior |
| Director of Research & Development | Brooklyn, New York, United States | Sep 1, 2026 | Oct 11, 2026 | Senior |
| Manager/Principal Scientist Research & Development - Polymer Formulation | Brooklyn, New York, United States | Sep 1, 2026 | Oct 11, 2026 | Senior |
| Senior Medical Device Research and Development Engineer | Brooklyn, New York, United States | Sep 1, 2026 | Oct 11, 2026 | Senior |
| Production Technician I, 2nd Shift Full-Time Monday-Friday | Brooklyn, New York, United States | Jul 30, 2026 | Oct 11, 2026 | Entry |
| Quality Assurance Technician | Brooklyn, New York, United States | Jul 31, 2025 | Oct 11, 2026 | Entry |
Connect
See your connections at Cresilon on LinkedIn (search by name, results not checked)